NCT03645395View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Non-hodgkin Lymphoma
Interventions
DRUG

MT-3724

Experimental treatment with MT-3724 in combination with LEN therapy.

Trial Locations (5)

21201

University of Maryland, Baltimore

33322

Boca Raton Clinical Research, Plantation

60612

Rush University, Chicago

75390

University of Texas Southwestern, Dallas

90603

Innovative Clinical Research Institute, Whittier

Sponsors
All Listed Sponsors
lead

Molecular Templates, Inc.

INDUSTRY